Oral vs Inhaled Asthma Therapy

[1]  S. Braman.  Drug Treatment of Asthma in the Elderly , 1996, Drugs.

[2]  W. Busse,et al.  Zileuton , 1996, The Lancet.

[3]  M. Weinberger,et al.  Does increased access to primary care reduce hospital readmissions? Veterans Affairs Cooperative Study Group on Primary Care and Hospital Readmission. , 1996, The New England journal of medicine.

[4]  L. Hendeles,et al.  Theophylline in asthma. , 1996, The New England journal of medicine.

[5]  A. Woolcock,et al.  Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. , 1996, American journal of respiratory and critical care medicine.

[6]  L. Fabbri,et al.  Methotrexate in the treatment of systemic glucocorticoid-dependent severe persistent asthma: a word of caution. , 1996, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[7]  Cochrane Gm.  Compliance and Outcomes in Patients with Asthma , 1996 .

[8]  J. Golish,et al.  Clinical management of asthma in the 1990s. Current therapy and new directions. , 1996, Drugs.

[9]  S. Spector.  Management of asthma with zafirlukast. Clinical experience and tolerability profile. , 1996, Drugs.

[10]  E. Walters,et al.  Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma. , 1995, American journal of respiratory and critical care medicine.

[11]  J. Rees,et al.  ABC of Asthma: TREATMENT OF CHRONIC ASTHMA , 1995, BMJ.

[12]  K. Chung,et al.  Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy. , 1995, American journal of respiratory and critical care medicine.

[13]  R. Djukanović,et al.  The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. , 1995, The European respiratory journal.

[14]  Pauwels,et al.  Deliberate non-compliance due to dislike of medications , 1995 .

[15]  Pauwels,et al.  Pros and cons of oral anti-asthma medication , 1995 .

[16]  G. Jones,et al.  Corticosteroid osteoporosis. , 1995, British journal of rheumatology.

[17]  K. Jones,et al.  Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group. , 1994, Thorax.

[18]  D. Hendrick,et al.  Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics. , 1994, American journal of respiratory and critical care medicine.

[19]  T. Haahtela,et al.  Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. , 1994, The New England journal of medicine.

[20]  S. Spector,et al.  Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. , 1994, American journal of respiratory and critical care medicine.

[21]  P. Ind,et al.  Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid , 1994, The Lancet.

[22]  N. Pearce,et al.  Confounding by severity does not explain the association between fenoterol and asthma death , 1994, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[23]  M. Calderón,et al.  Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma. , 1994, American journal of respiratory and critical care medicine.

[24]  S. Adlis,et al.  Comparison of patients' compliance with prescribed oral and inhaled asthma medications. , 1994, Archives of internal medicine.

[25]  S. Kesten,et al.  Regular vs as-needed inhaled salbutamol in asthma control , 1994, The Lancet.

[26]  H. Magnussen,et al.  Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. , 1994, American journal of respiratory cell and molecular biology.

[27]  C. Page,et al.  Anti-inflammatory effects of low-dose oral theophylline in atopic asthma , 1994, The Lancet.

[28]  A. Buist,et al.  A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists. , 1994, American journal of respiratory and critical care medicine.

[29]  G. Chiappara,et al.  Theophylline suppresses the release of tumour necrosis factor-alpha by blood monocytes and alveolar macrophages. , 1994, The European respiratory journal.

[30]  Regularly inhaled β-agonists with steroids are not harmful in stable asthma , 1994 .

[31]  M Heino.  Regularly inhaled beta-agonists with steroids are not harmful in stable asthma. , 1994, The Journal of allergy and clinical immunology.

[32]  R. Utiger.  Differences between inhaled and oral glucocorticoid therapy. , 1993, The New England journal of medicine.

[33]  M. Roth,et al.  Inhibition of natural killer cell activity by therapeutic levels of theophylline. , 1993, American journal of respiratory cell and molecular biology.

[34]  B. Mullen,et al.  The Association Between β-Agonist Use and Death From Asthma: A Meta-analytic Integration of Case-Control Studies , 1993 .

[35]  K P Jones,et al.  Guidelines on the management of asthma. , 1993, Thorax.

[36]  I. Pavord,et al.  Asthma control during and after cessation of regular beta 2-agonist treatment. , 1993, The American review of respiratory disease.

[37]  K. Kerrebijn,et al.  Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. , 1993, Thorax.

[38]  C F Robertson,et al.  Treatment of asthma in children and adolescents: the need for a different approach , 1993, The Medical journal of Australia.

[39]  H. Chrystyn,et al.  Investigations of an optimal inhaler technique with the use of urinary salbutamol excretion as a measure of relative bioavailability to the lung. , 1993, Thorax.

[40]  C. Page,et al.  Theophylline--an immunomodulatory role in asthma? , 1993, The American review of respiratory disease.

[41]  D. Hosking.  Effects of corticosteroids on bone turnover. , 1993, Respiratory medicine.

[42]  C. Print,et al.  Regular inhaled beta agonist in asthma: effects on exacerbations and lung function. , 1993, Thorax.

[43]  Samy Suissa,et al.  The Use of β‐Agonists and the Risk of Death and Near Death from Asthma , 1992 .

[44]  C. van Weel,et al.  Does the continuous use of bronchodilators mask the progression of asthma or chronic bronchitis? , 1992, Family practice.

[45]  J. Kemp,et al.  A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. , 1992, The New England journal of medicine.

[46]  P. O'Byrne,et al.  Formoterol compared with beclomethasone and placebo on allergen-induced asthmatic responses. , 1992, The American review of respiratory disease.

[47]  J. Palmer,et al.  A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group. , 1992, The European respiratory journal.

[48]  T. Haahtela,et al.  A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. , 1992, The Journal of allergy and clinical immunology.

[49]  P. Jeffery,et al.  Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. , 1992, The American review of respiratory disease.

[50]  P. Howarth,et al.  Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. , 1992, The American review of respiratory disease.

[51]  Pierre Ernst,et al.  The Use of β-Agonists and the Risk of Death and near Death from Asthma , 1992 .

[52]  M. Mullee,et al.  Correlates of asthma morbidity in primary care. , 1992, BMJ.

[53]  A. Verbeek,et al.  Bronchodilator treatment in moderate asthma or chronic bronchitis: continuous or on demand? A randomised controlled study. , 1991, BMJ.

[54]  J. Malo,et al.  A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. , 1991, The American review of respiratory disease.

[55]  T. Haahtela,et al.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.

[56]  D. Faulds,et al.  Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. , 1991, Drugs.

[57]  J. Costello.  Asthma—a United Kingdom View; Treatment and Its Implications , 1991, Annals of the New York Academy of Sciences.

[58]  J. Cramer.  Medication compliance in epilepsy. , 1991, Archives of internal medicine.

[59]  R. N. Brogden,et al.  Salmeterol xinafoate. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. , 1991, Drugs.

[60]  D. Dacruz,et al.  Guidelines for management of asthma. , 1990, BMJ.

[61]  R S Woodward,et al.  The effect of prescribed daily dose frequency on patient medication compliance. , 1990, Archives of internal medicine.

[62]  P. Venge,et al.  Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. The effects of antiasthmatic treatment with budesonide or terbutaline. , 1990, The American review of respiratory disease.

[63]  M. Turner‐Warwick.  Nocturnal asthma: a study in general practice. , 1989, The Journal of the Royal College of General Practitioners.

[64]  Ahmed Ar,et al.  Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. , 1989 .

[65]  A. Ahmed,et al.  Corticosteroids: a review with emphasis on complications of prolonged systemic therapy. , 1989, Annals of allergy.

[66]  B. Weeke,et al.  Fiberoptic bronchoscopy and bronchial mucosal biopsies in asthmatics undergoing long‐term high‐dose budesonide aerosol treatment , 1988, Allergy.

[67]  R. Strunk,et al.  Need for theophylline in severe steroid‐requiring asthmatics , 1988, Clinical allergy.

[68]  S. Ma,et al.  Corticosteroid complications in respiratory disease. , 1987 .

[69]  S. Larsson,et al.  Clinical consequences of inadequate inhalation technique in asthma therapy. , 1987, European journal of respiratory diseases.

[70]  R. Patterson,et al.  Natural history of asthma in patients requiring long-term systemic corticosteroids. , 1986, Archives of internal medicine.

[71]  W. Busse,et al.  Use of ipratropium bromide in asthma. Results of a multi-clinic study. , 1986, The American journal of medicine.

[72]  M. Newhouse,et al.  Control of asthma by aerosols. , 1986, The New England journal of medicine.

[73]  S. Allen,et al.  What determines whether an elderly patient can use a metered dose inhaler correctly? , 1986, British journal of diseases of the chest.

[74]  R. C. Hobbs.  Steroid-induced fractures and bone loss in patients with asthma , 1984 .

[75]  D. Pavia,et al.  Effects of various inhalation modes on the deposition of radioactive pressurized aerosols. , 1982, European journal of respiratory diseases. Supplement.

[76]  M. Newhouse,et al.  Optimal delivery of aerosols from metered dose inhalers. , 1981, Chest.

[77]  D. Pavia,et al.  How should a pressurized beta-adrenergic bronchodilator be inhaled? , 1981, European journal of respiratory diseases.

[78]  M. Weinberger,et al.  The value of maintenance theophylline in steroid-dependent asthma. , 1981, The New England journal of medicine.